Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metronomic capecitabine efficacy in non-metastatic breast cancer
PACTR202502755674107Phase 2Completed
- Sponsor
- Suez Canal University Hospital
- Start
- Jan 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of capecitabine in breast cancer and triple-negative breast cancer (TNBC) (2 arms), sponsored by Suez Canal University Hospital. Primary endpoint: 2-year disease-free survival. Started Jan 2020; status: completed.
02
Drugs
capecitabine
03
Conditions
breast cancertriple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on PACTR202502755674107.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202502755674107.